viernes, 31 de agosto de 2007
domingo, 26 de agosto de 2007
viernes, 24 de agosto de 2007
PsychiatryMatters.MD - Bipolar II Disorder: Epidemiology, Diagnosis and Management
PsychiatryMatters.MD - Bipolar II Disorder: Epidemiology, Diagnosis and Management
Resumen de lo que es una revisión del TB II. De ahí se obtiene el PDF
Resumen de lo que es una revisión del TB II. De ahí se obtiene el PDF
lunes, 20 de agosto de 2007
sábado, 18 de agosto de 2007
Use of intensive case management to reduce time in hospital in people with severe mental illness: systematic review and meta-regression -- Burns et al. 335 (7615): 336 -- BMJ
Use of intensive case management to reduce time in hospital in people with severe mental illness: systematic review and meta-regression -- Burns et al. 335 (7615): 336 -- BMJ
Intensive case management works best
when participants tend to use a lot of hospital care and
less well when they do not. When hospital use is high,
intensive case management can reduce it, but it is less
successful when hospital use is already low. The benefits
of intensive case management might be marginal in
settings that have already achieved low rates of bed use,
and team organisation is more important than the details
of staffing. It might not be necessary to apply the full
model of assertive community treatment to achieve
reductions in inpatient care.
Intensive case management works best
when participants tend to use a lot of hospital care and
less well when they do not. When hospital use is high,
intensive case management can reduce it, but it is less
successful when hospital use is already low. The benefits
of intensive case management might be marginal in
settings that have already achieved low rates of bed use,
and team organisation is more important than the details
of staffing. It might not be necessary to apply the full
model of assertive community treatment to achieve
reductions in inpatient care.
Cochrane Reviews: PsychiatryMatters.MD - Electroconvulsive therapy for schizophrenia
Cochrane Reviews: PsychiatryMatters.MD - Electroconvulsive therapy for schizophrenia: "The evidence in this review suggests that ECT, combined with treatment with antipsychotic drugs, may be considered an option for people with schizophrenia, particularly when rapid global improvement and reduction of symptoms is desired. This is also the case for those with schizophrenia who show limited response to medication alone. Even though this initial beneficial effect may not last beyond the short term, there is no clear evidence to refute its use for people with schizophrenia. The research base for the use of ECT in people with schizophrenia continues to expand, but even after more than five decades of clinical use, there remain many unanswered questions regarding its role in the management of people with schizophrenia."
Cochrane Reviews: PsychiatryMatters.MD - Music therapy for schizophrenia or schizophrenia-like illnesses
Cochrane Reviews: PsychiatryMatters.MD - Music therapy for schizophrenia or schizophrenia-like illnesses: "Music therapy as an addition to standard care helps people with schizophrenia to improve their global state and may also improve mental state and functioning if a sufficient number of music therapy sessions are provided. Further research should address the dose-effect relationship and the long-term effects of music therapy. "
Cochrane Reviews: PsychiatryMatters.MD - Cognitive behaviour therapy for schizophrenia
Cochrane Reviews: PsychiatryMatters.MD - Cognitive behaviour therapy for schizophrenia: "CBT is a promising but under evaluated intervention. Currently, trial-based data supporting the wide use of CBT for people with schizophrenia or other psychotic illnesses are far from conclusive. More trials are justified, especially in comparison with a lower grade supportive approach. These trials should be designed to be both clinically meaningful and widely applicable."
Cochrane Reviews: PsychiatryMatters.MD - Cessation of medication for people with schizophrenia already stable on chlorpromazine
Cochrane Reviews: PsychiatryMatters.MD - Cessation of medication for people with schizophrenia already stable on chlorpromazine: "This review confirms clinical experience and quantifies the risks of stopping chlorpromazine medication for a group of people with schizophrenia who are stable on this drug. With its moderate adverse effects, chlorpromazine is likely to remain one of the most widely prescribed treatments for schizophrenia."
Cochrane Reviews: PsychiatryMatters.MD - Topiramate for acute affective episodes in bipolar disorder
Cochrane Reviews: PsychiatryMatters.MD - Topiramate for acute affective episodes in bipolar disorder: "There is insufficient evidence on which to base any recommendations regarding the use of topiramate in any phase of bipolar illness, either in monotherapy or as an adjunctive treatment."
Cochrane Reviews: PsychiatryMatters.MD - New generation antipsychotics for first episode schizophrenia
Cochrane Reviews: PsychiatryMatters.MD - New generation antipsychotics for first episode schizophrenia
The results of this review are inconclusive. Whether the use of new generation antipsychotics really makes the treatment less off putting and enhances long-term compliance is unclear. Pragmatic, well-designed and reported long-term trials would be useful to answer this question.
The results of this review are inconclusive. Whether the use of new generation antipsychotics really makes the treatment less off putting and enhances long-term compliance is unclear. Pragmatic, well-designed and reported long-term trials would be useful to answer this question.
Cochrane Reviews: PsychiatryMatters.MD - Family intervention for schizophrenia
Cochrane Reviews: PsychiatryMatters.MD - Family intervention for schizophrenia
Clinicians, researchers, policy makers and recipients of care cannot be confident of the effects of family intervention from the findings of this review. Further data from already completed trials could greatly inform practice and more trials are justified as long as their participants, interventions and outcomes are applicable to routine care.
Clinicians, researchers, policy makers and recipients of care cannot be confident of the effects of family intervention from the findings of this review. Further data from already completed trials could greatly inform practice and more trials are justified as long as their participants, interventions and outcomes are applicable to routine care.
Cochrane Reviews: PsychiatryMatters.MD - Valproate for acute mood episodes in bipolar disorder
Cochrane Reviews: PsychiatryMatters.MD - Valproate for acute mood episodes in bipolar disorder
There is consistent, if limited, evidence that valproate is an efficacious treatment for acute mania. Valproate may be less efficacious than olanzapine. More, rigorously designed, trials over the full range of acute affective episodes are required.
There is consistent, if limited, evidence that valproate is an efficacious treatment for acute mania. Valproate may be less efficacious than olanzapine. More, rigorously designed, trials over the full range of acute affective episodes are required.
Suscribirse a:
Entradas (Atom)